CD28 Costimulation: From Mechanism to Therapy

Abstract

Summary Ligation of the CD28 receptor on T cells provides a critical second signal alongside T cell receptor (TCR) ligation for naive T cell activation. Here we discuss the expression, structure, and biochemistry of CD28 and its ligands. CD28 signals play a key role in many T cell processes including cytoskeletal remodeling, production of cytokines, survival, and differentiation. CD28 ligation leads to unique epigenetic, transcriptional, and post-translational changes in T cells that cannot be recapitulated by TCR ligation alone. We discuss the function of CD28 and its ligands in both effector and regulatory T cells. CD28 is critical for regulatory T cell survival and the maintenance of immune homeostasis. We outline the roles that CD28 and its family members play in human disease and we review the clinical efficacy of drugs that block CD28 ligands. Despite the centrality of CD28 and its family members and ligands to immune function, many aspects of CD28 biology remain unclear. Translation of a basic understanding of CD28 function into immunomodulatory therapeutics has been uneven with both successes and failures. Such real-world results may stem from multiple factors including complex receptor-ligand interactions among CD28 family members, differences between the mouse and human CD28 families, and cell-type specific roles of CD28 family members.

A Systemic Lupus Erythematosus Endophenotype Characterized by Increased CD8 Cytotoxic Signature Associates with Renal Involvement

“…This work highlights how a particular subpopulation of CD8 + T cells is potentially pathogenic in some lupus patients, and also presents a way to identify those subjects via whole blood flow cytometry and/or gene expression. Several therapies that target T cell activation are currently approved or in the pipeline (41), hence multiple lupus patients may benefit from a stratification approach using the biomarkers presented in this study. …”

Selective blockade of CD28 on human T cells facilitates regulation of alloimmune responses

“…With the progression of cellular therapies to the clinic, there is a concern regarding the effect CTLA4-Ig would have on Treg therapy for the treatment of immune pathologies, including transplant rejection. Hence, selective blockade of CD28 is theoretically advantageous, as it would preserve the coinhibitory signals delivered upon CTLA4 engagement (8). In this study, we investigate the effects of FR104 -a PEGylated monovalent humanized Fab' antibody fragment antagonist of CD28 (9) -in a humanized mouse transplantation setting, comparing its effects directly with CTLA4-Ig therapy.…”

Cytokines and Metabolic Factors Regulate Tumoricidal T-Cell Function During Cancer Immunotherapy

“…Tumoricidal T-cell functions are regulated by a series of potentiating and future science group Cytokines & metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy Review inhibitory signals delivered initially by dendritic cells in draining lymph nodes and subsequently by tumor cells and supporting stroma. Upon initial recognition by the TCR of cognate MHC-peptide complexes on dendritic cells, interaction of the T-cell costimulatory receptor CD28 with its ligands CD80 (B7-1) or CD86 (B7-2) provides a critical second signal that facilitates T-cell activation and cell cycle progression [55]. This initial activation also induces T-cell surface localization of the checkpoint receptor CTLA-4 that also binds B7-1/2 to temper the response and prevents excessive inflammation [56,57].…”